Medicaid coverage for ketamine treatment depends on which form of ketamine you’re talking about and which state you live in. The FDA-approved nasal spray version (Spravato) is generally covered by Medicaid programs across many states, while generic IV ketamine infusions are covered in far fewer states. In both cases, you’ll need prior authorization and must meet specific clinical criteria before coverage kicks in.
Spravato vs. IV Ketamine: Two Different Coverage Stories
There are two main forms of ketamine used to treat depression, and Medicaid treats them very differently.
Spravato is a nasal spray containing esketamine, a close chemical relative of ketamine. It received FDA approval in 2019 for treatment-resistant depression in adults. Because it has FDA approval, most state Medicaid programs cover it as a physician-administered drug. North Carolina Medicaid, for example, began covering Spravato as early as March 2019, shortly after it hit the market. When Medicaid does cover Spravato, out-of-pocket costs for beneficiaries are typically very low, usually between $0 and $10 per visit.
Generic IV ketamine infusions are a different situation. IV ketamine is used “off-label” for depression, meaning the drug itself is FDA-approved (as an anesthetic) but not specifically approved for treating mood disorders. Most state Medicaid programs have historically not covered IV ketamine infusions for depression. However, this is starting to change. Wisconsin’s Medicaid program, for instance, began covering IV ketamine infusion therapy for major depressive disorder effective January 1, 2025. Other states may follow, but coverage remains inconsistent.
Clinical Requirements for Approval
Even in states that cover ketamine treatment, you won’t get automatic approval. Medicaid programs require prior authorization, which means your provider must submit documentation proving you meet specific clinical criteria before treatment begins.
For treatment-resistant depression without suicidal thoughts, the requirements are typically strict. Using Wisconsin’s policy as a representative example, you must:
- Have a confirmed diagnosis of major depressive disorder
- Be at least 18 years old
- Have tried and failed at least two antidepressant medications from different drug classes (such as an SSRI and an SNRI, or one of those plus bupropion), each taken at the maximum tolerated dose for at least four weeks
- Not have an active substance use disorder
- Continue taking an oral antidepressant alongside the ketamine treatment
For people with major depressive disorder and active suicidal thoughts, the bar is somewhat lower. You still need a confirmed diagnosis, must be 18 or older, and cannot have an active substance use disorder, but you may not need to demonstrate the same history of failed medication trials. The rationale is that suicidal ideation creates more urgency.
How Many Treatments Medicaid Covers
Medicaid doesn’t approve open-ended ketamine treatment. Approvals come in defined blocks. In Wisconsin’s program, initial authorization covers three months and a maximum of eight treatments. If your provider can document that treatment is working, renewal authorization extends coverage for six months with up to 13 additional treatments. Your provider will need to submit a new request at each renewal, showing continued clinical benefit.
This structure reflects how ketamine therapy typically works in practice. Most treatment protocols start with a series of closely spaced sessions (often two to three per week), then taper to less frequent maintenance visits.
Coverage Varies Widely by State
Medicaid is not a single national program. Each state runs its own Medicaid plan with its own formulary and coverage decisions. This means the answer to whether ketamine treatment is covered depends heavily on your state. Some states fully cover Spravato. Others have limited or no coverage. And only a handful, like Wisconsin, have begun covering generic IV infusions.
Your best move is to contact your state Medicaid office or managed care plan directly and ask about coverage for both Spravato and IV ketamine. Your prescribing provider’s office can also check, since they handle prior authorization requests routinely and will know what your plan has approved in the past.
What to Expect Out of Pocket
When Medicaid does cover ketamine treatment, the cost to you as a beneficiary is minimal. Copayments for covered services typically fall in the $0 to $10 range per visit. This is a significant difference from paying out of pocket, where a single IV ketamine infusion can run $400 to $800 and a full initial course of six infusions can cost several thousand dollars.
If your state Medicaid program denies coverage, you have the right to appeal the decision. Your provider can help by submitting additional clinical documentation supporting why ketamine treatment is medically necessary in your case. Some patients have success on appeal, particularly when they can demonstrate a clear history of failed treatments with conventional antidepressants.